Dec 23, 2020
A2 Biotherapeutics Enters Into Collaboration Agreement With Merck To Develop Allogeneic Cell Therapy For Solid Tumor Cancers
Nov 05, 2020
Pappas Capital Portfolio Company VelosBio to be Acquired by Merck
Oct 15, 2020
Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment for Patients with Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
Sep 24, 2020
NEXPLANON® Contraceptive Arm Implant Now Available for Use in Canada
Sep 15, 2020
BRENZYS® (etanercept injection) now indicated for the Treatment of Plaque Psoriasis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis
Jul 14, 2020
Hackensack Meridian CDI has Struck a COVID-19 Research Collaboration with Merck
Jun 23, 2020
Linnaeus Therapeutics Announces Clinical Trial Collaboration Agreement with Merck to Evaluate LNS8801 in Combination with KEYTRUDA® in Patients with Advanced Cancer
Jun 16, 2020
Intermolecular Announces Breakthrough Four-Element ALD Chalcogenide-based OTS for 3D Memory Arrays
Jun 09, 2020
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy
May 29, 2020
Eisai Announces Updated Results of ENHANCE 1, a Phase 1b/2 Trial Investigating HALAVEN® (eribulin mesylate) plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Triple-Negative Breast Cancer at ASCO 2020
May 29, 2020
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors
May 28, 2020
Insights on the Worldwide Stable Isotope Labeled Compounds Industry to 2025 - Featuring PerkinElmer, Merck & 3M Among Others - ResearchAndMarkets.com
May 27, 2020
Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information to Help Inform Treatment Decisions for Women with MS
May 27, 2020
MilliporeSigma and Baylor College of Medicine Collaborate to Advance a Vaccine Manufacturing Platform to Fight Covid-19
May 27, 2020
The Merck Manuals Launches Season 2 of Medical Myths Podcast
May 23, 2020
New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks
May 19, 2020
NIIMBL Announces $10M in New Project Funding Towards Advances in Biopharmaceutical Manufacturing Innovation
May 15, 2020
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II
May 13, 2020
Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to Be Presented at ASCO 2020
May 13, 2020
OncoSec's TAVO(TM) Receives ATMP Certification from European Medicines Agency to Support Marketing Authorization Application in Metastatic Melanoma